. Subcortical ischemic strokes (60-85%), cognitive impairment (40-50%), migraine with aura (20-40%), depression (20%), and apathy (40%) are the most prevalent symptoms 1 . An increased risk of intracerebral hemorrhage (ICH) has also been reported in these patients 3, 4, 5, 6 . Clinical suspicion is based on typical symptoms, family history, and specific findings in magnetic resonance imaging (MRI) 1 . While family history is almost always present, de novo mutations have also been described 7, 8 . Genetic test assessing for NOTCH3 mutations or skin biopsy investigating the presence of granular osmiophilic material (GOM) are required for definitive diagnosis 1 . Management strategies consist of vascular risk factor (VRF) control, antiaggregation, and, when appropriate, genetic counseling.
To the best of our knowledge this is the first case series report of CADASIL in South America.
We describe clinical and demographic characteristics of 13 patients from 10 families with diagnosis of CADASIL from a single center in Argentina.
MethoD
Retrospective review of medical records and diagnostic tests of patients with CADASIL. Genetic test was not widely available in Argentina at the time of this report. Thus, most patients were diagnosed by skin biopsy samples. A single specialized laboratory studied all samples. Family history was documented in all cases. Patients or patient's relatives were contacted to complete missing information and to update vital status. All subjects provided consent. The ethics committee of the institution approved the study.
ReSuLtS
We report 13 patients (7 men) with diagnosis of CADASIL from 10 families, aged 48 ± 9 (40-73) years old at time of diagnosis (Table) . Follow up was between 3 months and 10 years. Diagnosis was established by skin biopsy in 11 patients, and by genetic testing performed abroad in two cases. Ultrastructural study of the skin biopsies showed GOM deposits, mainly in the thickened basement membrane of arteries or capillaries ( Figure 1 ).
All patients had European ancestry: Spanish (n = 8), Greek (n = 1), Russian/Polish (n = 2), Portuguese (n = 1), Ukrainian (n = 1). Three patients had no familiar history of symptoms suggestive of CADASIL. Initial clinical presentations were: ischemic stroke (n = 11), migraine with aura (n = 1), and cognitive complaint (n = 1). All stroke patients later developed other symptoms: cognitive complaint (n = 9), migraine with aura (n = 1), apathy (n = 4), and depression (n = 6).
Cognitive impairment was diagnosed by neurological examination in six patients and by neuropsychological testing in four. Five patients were men and five women.
All patients had brain MRI. Typical lesions were found in external capsule (n = 11) and temporal lobes (n = 10). Only two had microbleeds (Figure 2 ). Two patients reveled asymptomatic acute infarcts in routine follow-up MRIs. Associated vascular risk factor were hypertension (n = 7), dyslipemia (n = 9), smoking (n = 4), type 2 diabetes mellitus (n = 2) and patent foramen ovale (PFO) (n = 2). All patients received risk factor control and antiplatelet treatment. Two of them were empirically anticoagulated. Two patients died during follow up as result of intracranial hemorrhage (ICH), one was on aspirin and the other was on warfarin. Currently eleven patients are on aspirin or clopidogrel. Modified Rankin scale was < 3 in 9 surviving subjects and ≥ 3 in 2.
Six asymptomatic family members were evaluated (physical examination and brain MRI). One had chronic headache. A 38 year-old woman presented white matter lesions not-typical of CADASIL. Three relatives in two families underwent skin biopsy after MRI. It was normal in all cases.
DISCuSSIon
CADASIL clinical and imaging patterns in this Argentinean population of European ancestry appear similar to those described in Northern hemisphere populations. Three patients had no familiar history of CADASIL. False-negative family history is commonly documented in individuals presenting with features of CADASIL and is associated with initial misdiagnosis 9 . Stroke was the leading presenting symptom 1 . As no treatment to modify disease progression is available, our patients are under risk factor control and single antiplatelet treatment.
Cognitive impairment affects up to 50% of patients 1 . We found it in ten patients and it was the initial symptom in two. The latter findings are consistent with those reported in a single large family in Colombia
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. Depression and apathy are described in 20-50% and 40% of CADASIL patients respectively 1 . Incidences in our population were similar to those described in the literature.
The proportion of migraine with aura in CADASIL patients is five times higher than in general population 1 . Five of our patients had migraine, two with and three without aura. Our series supports findings reporting that migraine without aura frequency is slightly higher in CADASIL patients compared with the general population 11 . Increased risk of ICH in CADASIL patients is based on case reports and it has not been proved with controlled studies. Approximately 22 cases of ICH in CADASIL patients have been reported 3, 4 . In our series, one hypertensive male treated with warfarin and one non-hypertensive woman treated with aspirin died after ICH.
Genetic test screening for the 23 exons of the EGFR is the gold standard for the diagnosis of CADASIL (sensitivity and specificity of almost 100%) 1 . Skin biopsy has been restricted to patients with negative genetic test with highly suggestive features of CADASIL or identification of a new sequence of unknown significance 1 , with a 100% of specificity and 96% or more sensitivity 12, 13 . Operator skills, number of arteries examined, and adhesion to guidelines for GOM identification could influence the sensitivity of the technique 14 . Skin biopsy examined by experienced observers was a suitable option in our population as complete genetic test of all 23 exons is not available in Argentina. GOM deposits are located both in small and medium sized arteries and capillaries, in contact with vascular smooth muscle cells (VSMC) or within the thickened basement membrane. Vein walls may also be involved.
Cerebral MRI adds valuable information to clinical suspicion. Changes in external capsule and temporal pole were found in eleven and ten patients respectively. While the first one is an earlier less specific finding, temporal pole involvement has been described as a radiologic marker of CADASIL 15 . Microbleeds are detected in 31-69% of CADASIL patients 4 . We found them in two subjects (15%). The number of young patients (83% were under 55 year-old), an adequate hypertension control could explain the low incidence in our population. Two patients showed asymptomatic acute cerebral infarcts in DWI/MRI during follow-up. This finding has been reported in 10% of CADASIL patients compared with 8% of patients with small-vessel disease 16 . Prevalence of PFO in CADASIL is up to 47% 17 . We found it in two patients. This finding may be related to NOTCH receptor family participation in the cardiovascular system development 18 . Brain MRI was performed in six asymptomatic relatives of 3 different families. Only a 38 year-old female showed white matter lesions. Three of them underwent skin biopsy. It was normal in all cases. These findings are consistent with a recent report in which only 33% of patients that had undergone a multistep genetic counseling finally took the genetic test. Reasons for drop out were not reported 19 .
In conclusion, we report the first case series of patients with CADASIL in South America. Published data in our region is scant. This can be due to low suspicion threshold and limited access to diagnostic tools. As European ancestry is not highly prevalent in all South American countries there 
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may be a variable incidence of CADASIL within this region. The Amerindian and African contributions to the gene admixture in the population of Buenos Aires are 15% and 4% respectively 20 . Hence European ancestry in this population is an important factor to take into account.
If MRI is not available the number of misdiagnosis may be high. In countries where genetic test screening for all the
